Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 3/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3571310 | 0.98 | NOTUM (0.56) | NOTUMAKR1C3GFERCASP6NEK2 | |
| Dimethylformamide SCHEMBL27729919 | 0.87 | NOTUM (0.46) | NOTUMAKR1C3GFERCASP6NEK2 | |
| SCHEMBL77188 | 0.86 | GFER (0.53) | NOTUMGFERCASP6KDM4EALDH1A1 | |
| SCHEMBL21418385 | 0.84 | GFER (0.60) | NOTUMGFERCASP6KDM4ECYP2C19 | |
| Hydrochloric Acid SCHEMBL3575037 | 0.84 | ALDH1A1 (0.52) | NOTUMGFERCASP6KDM4EALDH1A1 | |
| SCHEMBL27629722 | 0.84 | ME3 (0.63) | NOTUMAKR1C3KDM4ECYP2C19HTT | |
| SCHEMBL1222301 | 0.83 | NOTUM (0.79) | NOTUMAKR1C3KDM4ECYP2C19MAPT | |
| SCHEMBL27712656 | 0.83 | NOTUM (0.54) | NOTUMAKR1C3NEK2KDM4ECYP2C19 | |
| SCHEMBL30957002 | 0.83 | MGLL (0.58) | GFERCASP6KDM4EALDH1A1MAPT | |
| SCHEMBL14862731 | 0.82 | NOTUM (0.57) | NOTUMAKR1C3KDM4ECYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665374-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | Endevica Bio, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2024173905-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | ENDEVICA BIO, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | claimed |
| EP-1968995-A1 | METHODS FOR THE SYNTHESIS OF ARGININE-CONTAINING PEPTIDES | F. Hoffmann-la Roche AG (CH) | 2008-09-17 | — | — | EP | claimed |
| WO-2007077112-A1 | METHODS FOR THE SYNTHESIS OF ARGININE-CONTAINING PEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | claimed |
| EP-4665374-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | Endevica Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025123051-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024177907-A2 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2007077112-A1 | METHODS FOR THE SYNTHESIS OF ARGININE-CONTAINING PEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1315750-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002018437-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | NOTUM 4118/4885AKR1C3 1316/4885GFER 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.